New drug combo aims to tackle tough lung cancer
NCT ID NCT07079475
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This study tests a new combination of two oral drugs, DZD6008 and sunvozertinib, in 160 adults with advanced non-small cell lung cancer that has certain EGFR mutations. The goal is to check safety, how the drugs move through the body, and whether they shrink tumors. It is the first time this combination is being tested in humans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Beijing Chest Hospital
RECRUITINGBeijing, Beijing Municipality, 101125, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
First Affilicated Hospital of China Medical University
NOT_YET_RECRUITINGShengyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hangzhou Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harbin Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangsu People's Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanjing Gulou Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sichuan Cancer Hospital
RECRUITINGChengdu, Sichuan, 6100042, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affilicated Hospital of Xi'An Jiaotong University
NOT_YET_RECRUITINGXi’an, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of Jilin University
NOT_YET_RECRUITINGChangchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital, Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Taizhou Hospital
RECRUITINGTaizhou, Zhejiang, 317000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DZD6008 combined with sunvozertinib
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer that has specific genetic changes.
What could go wrong
This is an early-phase trial (Phase I/II) with only 160 participants, so the combination may not prove effective or safe enough for wider use. Side effects are unknown and being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.